Gavriilidou Agni F M, Sokratous Kleitos, Yen Hsin-Yung, De Colibus Luigi
OMass Therapeutics, Oxford, United Kingdom.
Front Mol Biosci. 2022 Apr 14;9:837901. doi: 10.3389/fmolb.2022.837901. eCollection 2022.
The design of new therapeutic molecules can be significantly informed by studying protein-ligand interactions using biophysical approaches directly after purification of the protein-ligand complex. Well-established techniques utilized in drug discovery include isothermal titration calorimetry, surface plasmon resonance, nuclear magnetic resonance spectroscopy, and structure-based drug discovery which mainly rely on protein crystallography and, more recently, cryo-electron microscopy. Protein-ligand complexes are dynamic, heterogeneous, and challenging systems that are best studied with several complementary techniques. Native mass spectrometry (MS) is a versatile method used to study proteins and their non-covalently driven assemblies in a native-like folded state, providing information on binding thermodynamics and stoichiometry as well as insights on ternary and quaternary protein structure. Here, we discuss the basic principles of native mass spectrometry, the field's recent progress, how native MS is integrated into a drug discovery pipeline, and its future developments in drug discovery.
在纯化蛋白质-配体复合物后,直接使用生物物理方法研究蛋白质-配体相互作用,可为新治疗分子的设计提供重要信息。药物发现中常用的成熟技术包括等温滴定量热法、表面等离子体共振、核磁共振光谱以及基于结构的药物发现,后者主要依赖蛋白质晶体学,最近还依赖冷冻电子显微镜。蛋白质-配体复合物是动态、异质且具有挑战性的系统,最好用几种互补技术进行研究。原生质谱(MS)是一种通用方法,用于研究处于天然折叠状态的蛋白质及其非共价驱动的组装体,提供有关结合热力学和化学计量的信息以及对蛋白质三级和四级结构的见解。在此,我们讨论原生质谱的基本原理、该领域的最新进展、原生质谱如何融入药物发现流程以及其在药物发现中的未来发展。